UNCY Stock Analysis
UN
Uncovered
Unicycive Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Unicycive Therapeutics, Inc. is a biotechnology company dedicated to developing treatments for certain medical conditions. The Company is focused on identifying medical conditions within and outside of kidney disease. Its development programs are focused on the development of two therapies: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD), and UNI 494, for treatment of acute kidney injury (AKI). Renazorb was initially developed by, and licensed from, Spectrum Pharmaceuticals. UNI 494 was initially developed by, and licensed from Sphaera Pharmaceuticals, respectively. CKD is the gradual loss of kidney function, which leads to electrolyte imbalances, fluid build-up, anemia, bone disease, and heart disease. Hyperphosphatemia is an electrolyte disorder in which untreated elevated phosphate levels in the blood lead to cardiovascular complications and vascular calcification.